← Back to Home

Reducing Repeat Airway Surgeries: FDA Grants Accelerated Approval to DNA Immunotherapy VOCERYQ

By helping the immune system recognize infected cells, the therapy offers patients with recurrent respiratory papillomatosis a new option to reduce their surgical burden. In a small trial, 7 of 26 patients evaluated for efficacy required no surgery for one year. Whether the effect can be sustained remains a question for confirmatory research.

By SURL BioNews

For patients with recurrent respiratory papillomatosis, removing growths in the airway often provides only a respite before the next surgery. On October 30, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to INOVIO’s VOCERYQ to reduce the frequency of papilloma removal surgeries in adult patients. It is the first plasmid DNA immunotherapy approved in the United States, offering another treatment pathway to reduce the surgical burden of this rare chronic disease.

The disease is primarily caused by human papillomavirus (HPV) types 6 and 11. Lesions often develop in the larynx, particularly near the vocal cords, and may cause hoarseness, chronic cough, and, in severe cases, difficulty breathing. Surgery can remove papillomas, but the virus may remain in the tissue, leading patients to undergo repeated procedures over many years. VOCERYQ is designed to help the immune system better recognize and attack infected cells.

The therapy contains two plasmid DNAs that provide instructions for producing HPV-related antigens and interleukin-12 (IL-12), which enhances the immune response, respectively. Administration requires the CELLECTRA 5PSP device, combining intramuscular injection with brief electrical pulses to help DNA enter cells. This technique, known as “electroporation,” temporarily creates reversible pores in cell membranes. The approved regimen consists of four doses of 6.25 milligrams each, administered on day 0 and at weeks 3, 6, and 9. The prescribing information also requires surgical removal of visible lesions before the first dose to minimize residual lesions.

RRP-001, the trial supporting approval, was a multicenter, open-label, single-arm study that enrolled 32 adults. Of these, 26 had undergone at least three papilloma removal surgeries in the year before treatment and were included in the efficacy analysis. Their median number of surgeries in the preceding year was 4.5. Among these 26 patients, 7, or 27%, required no further removal surgery during the 12-month follow-up period after treatment. The study’s term “complete response” means that no surgery was required during this period; it does not establish that the virus was cleared or the disease was cured.

The result provides evidence of reduced surgical need, but the small sample size and lack of a concurrent randomized control group limit assessments of the magnitude and duration of the effect. Safety data came from all 32 treated participants: injection-site reactions occurred in 34%, headache in 19%, fatigue in 16%, and hypertension in 13%. The electroporation procedure may also cause brief muscle contractions, local bleeding, or vagal reactions. Safety and efficacy in pediatric patients have not yet been established.

Accelerated approval also carries an obligation for further verification. The FDA requires a confirmatory study enrolling at least 50 adult and pediatric patients who had undergone at least three surgeries in the year before treatment. The study should track the need for surgery for at least three years after completion of the treatment course and compare the results with an appropriate external control group or a scientifically justified threshold. A draft trial protocol must be submitted by December 30, 2026. The study is scheduled for completion on December 30, 2031, with the final report due by August 30, 2032.

In an announcement filed with the SEC, INOVIO said it expected to begin accepting orders and shipping approximately 60 days after approval, with a full commercial launch in the first quarter of 2027. For patients, the longer-term question is whether the improvement of one year without surgery can extend into years of stable disease control. Continued approval may depend on whether the confirmatory study verifies clinical benefit. If the study fails to confirm benefit or does not proceed as required, the FDA may withdraw approval.

References

  1. INOVIO announcement filed with SEC
  2. U.S. Food and Drug Administration
  3. U.S. Food and Drug Administration
  4. U.S. Food and Drug Administration